In The Hill, Catalyst’s Jeff Myers argues it’s unlikely early COVID-19 treatments will have remarkably high efficacy, but it’s still worth making and having them be available options to combat the deadly coronavirus. “I think the first drug out of the chute is not going to be a magic bullet; it’s going to be a start,” he said. “But you’re more likely to get products that can treat symptoms way faster than you’re going to get a vaccine.”

Read the full article here.